Since the introduction of 5-iodo-2'-deoxyuridine as an antiviral agent in 1961 (12) , several other compounds have been developed to treat herpes simplex virus (HSV) infections, including adenine arabinoside (20) , adenine arabinoside 5'-monophosphate (14) , trifluorothymidine (28) , acyclovir (9) , (E)-5-(2-bromovinyl)-2'-deoxyuridine (8) , phosphonoformate (PFA) (18) , and phosphonoacetic acid (PAA) (22) . Because some of these compounds are toxic to normal cells at antiviral concentrations, numerous investigators have sought synergistic combinations of drugs to allow effective chemotherapy of herpesvirus infections at lower (subtoxic) drug concentrations (1-4, 7, 11, 15, 16, 21, 26) . Such a strategy has been highly successful in the treatment of bacterial diseases and cancer. A potential problem in viral chemotherapy is the emergence of drugresistant strains (5, 6, 10, 13, 25) . Since the modes of action of several of the antiviral compounds are quite different from each other, synergistic drug combinations might reduce the frequency with which clinically troublesome drug-resistant strains emerge. We have developed a novel nucleoside analog, BIOLF-62, which is extremely potent against HSV types 1 and 2 (HSV-1 and HSV-2) (24; K. K. Ogilvie, U. 0. Cheriyan, B. K. Radatus, K. 0. Smith, K. S. Galloway, and W. L. Kennell, submitted for publication) and two equine herpesvirus types (K. 0. Smith, K. S. Galloway, and S. L. Hodges, submitted for publication). Since its mode of action is different from that of phosphonoformate and phosphonoacetate (10, 24) , we investigated the possibility that BIOLF-62 might be synergistic with phosphonoformate or phosphonoacetate or both. This paper presents data which show the high degree of synergy between these compounds when used in vitro against HSV-1 and HSV-2. Ill.) were used in this study. A 3 mg/ml stock solution of each drug was prepared as follows: 3 mg of ACG was dissolved in 0.1 ml of 0.1 N NaOH and brought to volume with complete Eagle basal medium (BME); 3 mg of PAA and PFA were dissolved in 1 ml of complete BME; 3 mg of BIOLF-62 and BVDU were dissolved in 1 Viral plaque titrations. The titers of all HSV strains were determined by a plaque titration method (19) . Tissue culture dishes (35 by 10 mm; Corning Glass Works, Corning, N.Y.) were seeded with cells and used for assays when they were approximately 75% confluent. Volumes (0.2 ml) of logarithmic dilutions of each virus strain were inoculated onto each of two tissue culture dishes and adsorbed for 1 h with intermittent shaking. The inoculum was removed, and 2 ml of complete BME containing 0.5% human immune serum globulin (USP immunoglobulin, used according to reference 19, to prevent secondary plaque formation in the assay) was added. After a 48-h incubation period at 36°C in a 5% CO2 atmosphere, the overlay medium was removed, and the cell-sheets were stained with a 0.05% aqueous crystal. violet solution. The plaque numbers were counted with the aid of a Nikon profile projector which magnified the dishes 10 times. Duplicate results were averaged, and the number of PFU was calculated.
MATERIALS AND METHODS

BIOLF
Determination of viral EDSO. Tissue culture dishes (35 by 10 mm) with HFF cell monolayers at 75% confluence were inoculated with approximately 50 PFU of virus per 0.2 ml, and the virus was allowed to adsorb for 1 h with intermittent shaking. After removal of the inoculum, 2 ml of complete BME with 0.5% immune globulin and threefold dilutions of the appropriate drug was added to duplicate dishes. One set of dishes received no drug and was later used for the "no-drug control." After a 48-h incubation period at 36°C in a 5% CO2 atmosphere, the overlay medium was removed, the cells were stained as described above, and plaques were, counted. After averaging the counts of duplicate plates, the fraction of plaques emerging in the presence of each drug dilution was calculated as a percentage of the control. Each drug titration was plotted on semilogarithmic graph paper.
The viral 50%6 effective dose (ED3,) concentration was that amount of drug per milliliter of overlay medium that inhibited plaque numbers by 50%o compared with no-drug controls. This was interpolated from the graphic plot of the data.
Synergim studie. Tissue culture dishes (35 by 10 mm) were seeded with HFF cells and used for assays when they were approximately 75% confluent. Volumes (0.2 ml) of logarithmic dilutions of the virus strain were inoculated onto tissue culture dishes and adsorbed for 1 h with intermittent shaking. After removal of the inoculum, 2 ml of complete BME with 0.5% immune globulin and dilutions of the appropriate separate drug or drug combinations was added to duplicate dishes. One set of dishes received no drug and was later used for the no-drug control. After a 48-h incubation period at 36°C in a 5% CO2 atmosphere, the overlay medium was removed, the cells were stained as described above, and plaques were counted. After averaging the counts of duplicate plates, the virus titer was determined (PFU per milliliter). Then the fold titer reduction was calculated by dividing the virus titer of the no-drug control by the virus titer in the presence of the drug or drug combination. By definition, the fold titer reduction of the no-drug control is 1.
RESULTS
Effects of combining BIOLF-62 with PAA, BVDU, or ACG. Five to ten ED50 of PAA, BVDU, and ACG was used separately to determine the fold titer reduction of HSV-1 Patton; reduction in virus titer by use of each drug alone was found to be 31-to 130-fold over the no-drug control (Table 1) . When BIOLF-62 and PAA were used in combination, however, virus titer reduction was more than 9,200-fold, demonstrating substantial synergy. There was only a slight synergistic effect against HSV-1 when BIOLF-62 was combined with either BVDU or ACG.
The large synergistic effect of BIOLF-62 and (Table 2) . However, the maximum synergistic effect observable by the plaque reduction method is probably limited to the region of 100-to 1,000-fold (see Discussion).
Effects of combining PFA with BIOLF-62, ACG, or BVDU. PAA and PFA reportedly have identical modes of action, yet PFA is less toxic than PAA in vivo (10) . Therefore, PFA was studied as a substitute for PAA in in vitro synergy studies because PFA might be more useful in combination with other drugs in vivo. HSV-1 Patton was tested against PFA individually and in combination with BIOLF-62, ACG, and BVDU (Table 3) . BIOLF-62 was highly synergistic with PFA, similar to its combined effect with PAA ( Table 1 ). The BVDU-PFA combination showed only a slight synergistic effect; ACG plus PFA showed no plaque reduction enhancement beyond the effect of each drug used separately; in fact, the two drugs appeared to be slightly antagonistic.
The potent combined effect of BIOLF-62 and PFA against HSV was studied further by examining the effect against two HSV-2 strains (Table  4) . Again, HSV-1 Patton was extremely sensitive to the combination of BIOLF-62 and PFA. In addition, two different strains of HSV-2 were extremely susceptible to this combination. In each case, the fold virus titer reduction was far beyond that which would be expected if the effect were simply additive.
Combining BVDU with PAA or BIOLF-62:
effects on HSV-2 G. BVDU is known to be about two orders of magnitude less effective against HSV-2 strains than against HSV-1 strains (8) and for that reason has been used to differentiate the two types (D. R. Mayo, Abstr. Annu. Meet. Am. Soc. Microbiol. 1982, C119, p. 291). Therefore, a combination of BVDU and PFA was used against an HSV-2 strain to determine whether PFA would significantly enhance the effect of BVDU. The combined effect on HSV-2 G was substantially greater than additive by a factor of over 50-fold (Table 5) . As before, BIOLF-62 plus PFA was highly synergistic; BIOLF-62 plus BVDU had only a slightly greater inhibitory effect on HSV-2 G than did the individual drugs alone ( (23, 27) , and cell sheets cannot develop visible plaques. Therefore, the maximum synergistic effect that could be demonstrated by a plaque reduction assay method is probably 102_ BIOLF-62, 2.5 ,ug/ml; PFA, 80 ,ug/ml; BVDU, 2.5 ,ug/ ml.
I Fold titer reduction = virus titer of no-drug control divided by virus titer in presence of drug(s).
to 103-fold greater than that displayed by the additive effect of each drug alone. This is the range in which we observed synergism between BIOLF-62 and either PFA or PAA in the present work (Tables 1 to 5 ). A method other than simple plaque reduction will have to be used to determine the full extent of this synergism.
PFA had only a slight synergistic effect with BVDU against HSV-1 Patton (Table 3) . Howeer, there was a large synergistic effect between PFA and BVDU on HSV-2 G (52-fold over a simple additive effect). This great enhancement of BVDU efficacy against HSV-2 in vitro suggests that BVDU, if combined with PFA, might be much more attractive than either one alone for the treatment of human venereal or congenital herpesvirus disease.
